



Financial Tear Sheet

Corporate Profile

AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs across a range of therapeutic areas, including women’s health, all while delivering value to our shareholders.

Linda Lennox
Vice President, Investor
Relations & Corporate
Communications

Phone: 617-498-2846

Email:

llexnox@amagpharma.com

Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicines for complex yet under-treated health conditions across a range of therapeutic areas including anemia, pregnancy complications, women’s sexual function and menopause-related issues. We also work with patients and healthcare experts to break down barriers to care for the communities we serve through focused education and support programs.”

As we have grown, we have continued to invest in promising therapies at various stages of development and advance them through the clinical and regulatory process to deliver new treatment options to patients.

Stock Information

AMAG (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$24.10
Change (%)	▼ 0.05 (0.21%)
Volume	221,516
52 Week Low	\$11.93
Market Cap	\$832,518,531
Rolling EPS	-7.16
PE Ratio	0
Shares Outstanding	34,472,817



Data as of August 20, 2018 12:11 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News & Upcoming Events

August 06, 2018

There are currently no events scheduled.

AMAG Pharmaceuticals Completes Divestiture of
Cord Blood Registry®

August 06, 2018

AMAG Pharmaceuticals Appoints Brian Robinson,
M.D. as Senior Vice President of Medical Affairs

August 02, 2018

AMAG Pharmaceuticals Announces Second Quarter
2018 Financial Results and Provides Corporate
Update

SEC Filings

Filing Date	Form
August 09, 2018	8-K
August 08, 2018	4
August 03, 2018	10-Q
August 03, 2018	S-8